Related Experiment Video
Updated: May 11, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients
Journal of Neurology, Neurosurgery, and Psychiatry
|May 25, 2013
Summary
Mycophenolate mofetil (MMF) significantly reduced relapse rates in multiple sclerosis (MS) patients. This study suggests MMF is a safe and effective alternative therapy for managing MS symptoms and disability.
Area of Science:
- Immunology
- Neurology
- Pharmacology
Background:
- Multiple Sclerosis (MS) is a chronic neurological disease.
- Immunosuppressive agents are used for MS treatment.
- Mycophenolate mofetil (MMF) is an immunosuppressant with limited efficacy data in MS.
Purpose of the Study:
- To assess the safety and efficacy of MMF in MS patients.
- To evaluate MMF's impact on relapse rates and disability progression.
- To compare MMF efficacy with prior immunosuppressant treatments.
Main Methods:
- Retrospective study across three French MS centers.
- Compared annualised relapse rate (ARR) 1 year before and after MMF initiation.
- Assessed MMF safety and Expanded Disability Status Scale (EDSS) progression.
- Subgroup analysis for patients with prior immunosuppressant use.
Main Results:
- MMF significantly reduced ARR from 1.11 to 0.35 (p<0.0001).
- Adverse events occurred in 11% of patients, mainly gastrointestinal issues and infections.
- EDSS remained stable in patients without prior immunosuppressant treatment.
Conclusions:
- MMF demonstrates efficacy in reducing relapses for MS patients.
- MMF can improve or stabilize MS, serving as an alternative therapy.
- MMF offers a favorable safety profile for MS management.
Keywords:
Multiple SclerosisRelated Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...